ADMA Biologics Faces Securities Fraud Lawsuit After Stock Plunge

ADMA Biologics, Inc. is facing a securities fraud class action lawsuit filed on behalf of investors after a significant decline in its stock price. The lawsuit, lodged by law firm Bleichmar Fonti & Auld LLP, alleges potential violations of federal securities laws.

The complaint, filed in the U.S. District Court for the District of New Jersey, claims that ADMA Biologics and certain executives engaged in securities fraud. The allegations stem from a report by research firm Culper Research, which accused the company of "channel stuffing." This practice allegedly involves ADMA inducing distributors to purchase excess inventory by offering rebates and extended payment terms, thereby artificially inflating reported revenue.

According to Culper Research, without the alleged channel stuffing, ADMA's 2025 revenue would have shown a 3% decrease, contrary to the company's reported 20% growth. This revelation triggered a sharp sell-off in ADMA's stock. On March 24, 2026, shares dropped 16.6%, followed by a further 15% decline the next day, and an additional 13.9% fall after Cantor Fitzgerald downgraded the stock due to concerns raised by the short report. The cumulative drop reached approximately 29%.

ADMA Biologics is a biopharmaceutical company focused on manufacturing, marketing, and developing specialty biologics, including its flagship product ASCENIV, a treatment for primary humoral immunodeficiency. The lawsuit asserts that the company used channel stuffing to boost revenue amidst declining demand and failed to disclose related-party transactions.

Investors who purchased ADMA Biologics stock are encouraged to seek more information. The deadline to ask the court to be appointed lead plaintiff in the case is August 10, 2026. Lawyers emphasize that representation is on a contingency fee basis, meaning clients incur no upfront costs.